

図5. 左上腹内臓全摘術(LUAE)

IV. 吻合など

胃癌病巣は完全には切除できないが，癌が残っても定型通り切除して，後の化学療法につなげることや，病巣切除は目的としない「吻合術」(バイパス)も行われる．ここでは，「吻合術」[7](図6)について述べる．

適　応：病巣が幽門・前庭に限局していて，胃切除はできそうにないが，狭窄があり，食べられない症例．鼻腔チューブをなくしたい症例．食事をしながら化学療法を行いたい症例．

手術法：もっとも簡単には，胃上部の癌がなさそうな部位に空腸を持ち上げて側々吻合するものである．この方法では食べにくかったり，癌が吻合部に浸潤して機能をなくすことがあるので，できるだけ「胃を離断して吻合する方法」を採用している．

図6に示すように，癌病巣より口側の非癌部で胃を横断切離し，それぞれに空腸を吻合する．

結　果：手術法が吻合術にもかかわらずやや複雑であり，時間がかかる．しかし，手術後の経口摂取はまず保障される．病巣を含む肛門側も吻合しておくほうが安全である．

V. 術後併用療法

従来から「術後併用療法」は多数の症例で行われてきたが，ほとんどその結果は明らかでなかった．JCOGで行われた試験は3篇報告されているが，いずれも有意性を認めないとされている．使用された薬剤は，MMC+5-FU+cytosine arabinoside(CA)，tegafur，UFTなどであるが，対象が比較的進行度が軽い(stage I-III)症例であったことも原因と考えられる．最近行われた二つの臨床試験は，「有効」の結果が出たので紹介する．

1. 根治手術+UFT vs 手術のみ(N-SAS)[8]

対　象：根治手術できたT2・n1-2の症例

治療法：手術+UFT群と手術単独群の比較(第III相試験)．エンドポイントは生存期間である．各群244例集積

結　果：途中，登録がすすまなかったり，次の薬剤の出現もあって，合計188例(各群93例)で終了した．中間解析で「治療群」が4年生存率で



図6. 離断吻合

有意に上回った(84.5% vs 68.1%；$p=0.004$)．Grade 4の下痢が治療群にみられた(1例；1.1%)．

考　案：予定よりかなり小さい症例での結果であるが，治療群が生存率で勝っていた．対象が限られた症例であることや，症例数が少ないことから改めて比較試験のデータが出ることが望ましいと考えられる．

2. TS-1胃癌術後化学療法比較試験

対　象：根治手術できたstage II(T1除く)，IIIA，IIIB症例

治療法：手術＋TS-1群と手術単独群の比較(第III相試験)．エンドポイントは生存期間である．各群500例以上

結　果：1,000例を超える症例集積があった．中間解析での結果がもうすぐ発表される．

おわりに

胃癌の手術方法は，「経験的」に術式が提唱されたもので，従来の術式と比べてどれだけ優れているかを示すものではなかった．最近，「ガイドライン」が作成され，その中には「エビデンスに基づく治療法を記載する」とあって，すべての手術法を見直すよい機会になった．ここでは，まだ少ないながら地道な「臨床試験」を経て得られた「新しい治療法」を示した．これからは「臨床試験」を経ない胃癌の治療法は消えていく運命にあると考えられる．

◆◆◆ 文献 ◆◆◆

1) 日本胃癌学会：胃癌治療ガイドライン，第2版，金原出版，東京，2004
2) Furukawa H, Hiratsuka M, Imaoka S et al：Limited surgery for early gastric cancer in

cardia. Ann Surg Oncol 5：338-341, 1998
3) Furukawa H, Hiratsuka M, Imaoka S et al：Phase II study of limited surgery for early gastric cancer；segmental gastric resection. Ann Surg Oncol 6：166-170, 1999
4) Hiratsuka M, Miyashiro I, Furukawa H et al：Application of sentinel node biopsy to gastric cancer surgery. Surgery 129：335-340, 2001
5) Sasako M, Sano T, Furukawa H et al：Randomized phase III trial of standard D2 versus D2＋para-aortic lymph node(PAN) dissection(D) for clinically M0 advanced gastric cancer；JCOG9501. ASCO Proceedings, #LBA4015, 2006
6) Furukawa H, Hiratsuka M, Iwanaga T et al：Extended surgery；left upper abdominal exenteration plus Appleby's method；for type 4 gastric carcinoma. Ann Surg Oncol 4：209-214, 1997
7) 古河　洋，今村博司，清水潤三ほか：胃・空腸吻合―バイパス術．外科治療 88：204-208, 2003
8) Kinoshita T, Nakajima T, Ohashi Y et al：Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer；results of a randomized trial by national surgical adjuvant study for gastric cancer. ASCO Proceedings, #4021, 2005

*　　*　　*

お知らせ

◆第107回日本外科学会

会　　期：2007年4月11日(水)～13日(金)
会　　場：大阪国際会議場，リーガロイヤルホテル大阪
会　　長：門田守人(大阪大学大学院外科学講座消化器外科学)
メインテーマ：「社会と共に進化する外科学」
演題募集：終了しました．
参加登録：事前参加登録は行いません．すべて当日登録となります．
プログラム概要：
①特別講演(指定)，②招請講演(指定)，③特別企画(指定)，④国際シンポジウム(指定)，⑤シンポジウム(公募)，⑥ビデオシンポジウム(公募，一部指定)，⑦パネルディスカッション(公募)，⑧ワークショップ(公募)，⑨一般演題・口演/ビデオ/デジタルポスターセッション(公募)，⑩その他(生涯教育コース/卒後教育セミナー)，⑪市民公開講座〔2007年4月14日(土)午後，松下IMPホールにて〕，⑫トラベルグラント
問い合せ先：〒565-0871 吹田市山田丘2-2，E2
大阪大学大学院外科学講座消化器外科学
第107回日本外科学会定期学術集会事務局
TEL：06-6877-2739/FAX：06-6875-4175
E-mail：2007jss@surg2.med.osaka-u.ac.jp
http：//www2.convention.co.jp/jss2007/

Annals of Surgical Oncology 14(2):355–361
DOI: 10.1245/s10434-006-9209-3

Influence of Overweight on Surgical Complications for Gastric Cancer: Results From a Randomized Control Trial Comparing D2 and Extended Para-aortic D3 Lymphadenectomy (JCOG9501)

Toshimasa Tsujinaka, MD,[1] Mitsuru Sasako, MD,[2] Seiichiro Yamamoto, PhD,[3] Takeshi Sano, MD,[2] Yukinori Kurokawa, MD,[3] Atsushi Nashimoto, MD,[4] Akira Kurita, MD,[5] Hitoshi Katai, MD,[2] Toshio Shimizu, MD,[6] Hiroshi Furukawa, MD,[7] Satoru Inoue, MD,[8] Masahiro Hiratsuka, MD,[9] Taira Kinoshita, MD,[10] Kuniyoshi Arai, MD,[11] and Yoshitaka Yamamura, MD,[12] for the Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group

[1]Department of Surgery, Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka 540-0006, Japan
[2]Gastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan
[3]Cancer Information and Epidemiology Division, National Cancer Center Research Institute, Tokyo, Japan
[4]Department of Surgery, Niigata Cancer Center Hospital, Niigata, Japan
[5]Department of Surgery, National Shikoku Cancer Center, Matsuyama, Japan
[6]Department of Surgery, International Medical Center of Japan, Tokyo, Japan
[7]Department of Surgery, Sakai Municipal Hospital, Sakai, Japan
[8]Department of Surgery, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan
[9]Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan
[10]Department of Surgery, National Cancer Center East, Tokyo, Japan
[11]Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
[12]Department of Surgery, Aichi Cancer Center, Aichi, Japan

Background: The impact of overweight on the outcome of gastrectomy with lymphadenectomy is controversial, and data from a well-controlled, randomized study are needed to identify a possible relationship.

Methods: We used data from 523 patients registered for a prospective randomized trial comparing D2 and extended para-aortic D3 lymphadenectomy to compare the effects of body mass index (BMI) and the extent of lymphadenectomy for the development of general or major surgical complications (anastomotic leakage, abdominal abscess, and pancreatic fistula).

Results: Seventy-seven patients were classified as overweight with BMI ≥ 25, and 38 and 39 of these patients underwent a D2 or D3 lymphadenectomy, respectively. Among the 446 patients classified as nonoverweight with BMI < 25, 225 received D2 and 221 received D3 lymphadenectomy. Surgical complications, operation time, and blood loss were statistically significantly associated with BMI, and logistic regression analysis revealed that overweight directly affected the occurrence of surgical complications even after considering operation time

Received July 27, 2006; accepted July 27, 2006; published online December 5, 2006.
Members of the Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group are listed in the Acknowledgments.
Address correspondence and reprint requests to: Toshimasa Tsujinaka, MD, E-mail: toshi@onh.go.jp

and blood loss as intermediate factors instead of outcome variables. Among patients undergoing D2 lymphadenectomy, being overweight increased the risk for surgical complications and blood loss, whereas overweight was associated with only blood loss and operation time among patients receiving D3 lymphadenectomy.

Conclusions: Overweight increased the risk of surgical complications in patients undergoing gastrectomy both directly and indirectly through operation time and blood loss. The impact of overweight on surgical complications was more evident in patients undergoing a D2 dissection.

Key Words: Overweight—BMI—Complication—Gastric cancer—RCT—JCOG.

The incidence of overweight and obesity has been increasing in the general population, but the impact of overweight on surgical outcomes is unclear. Cancer surgery in overweight patients often takes longer and is associated with greater blood loss than in lean individuals as a result of the presence of excessive fat tissue impairing surgical procedures and lymph node dissection. The influence of overweight on the outcomes, e.g., surgical complications, surgical quality, hospital stay, and prognosis, of gastrectomy with D2 lymph node dissection for patients with gastric cancer is controversial.[1–5] These data were derived retrospectively from a single institution, but the surgical procedures and disease stages varied.

A prospective study from multiple institutions that use a similar surgical procedure is the ideal means to assess the impact of overweight on surgical outcomes and overall prognosis. A randomized trial, Japan Clinical Oncology Group (JCOG) 9501, was launched in 1995 to explore the potential survival benefit of extended para-aortic D3 dissection over standard D2 dissection. This trial provided the opportunity to prospectively evaluate collected data regarding the effect of overweight on surgical outcome after D2 or D3 dissection. Because a patient's physical condition, including body mass index (BMI), could affect treatment indications for either D2 or D3, an observational study may not correctly compare potential differences between groups. Thus, we used the JCOG data to investigate the interaction of D2/D3 dissection and overweight on surgical complications in a randomized trial. In addition, we examined whether overweight directly influences the occurrence of complications or if the effects of overweight may be mediated by associated factors, such as operation time and blood loss.

PATIENTS AND METHODS

Between June 1995 and April 2001, a total of 523 patients registered in the JCOG9501 study were randomly allocated to either D2 (n = 263) or D3 dissection (n = 260) by balancing the groups according to institution, tumor growth pattern (expansive vs. infiltrative growth) and tumor (T) stage (cT2b vs. cT3/cT4). Patients aged < 76 years with histologically proven and resectable primary gastric carcinoma with an estimated depth of SS (invading subserosa: cT2b), SE (penetrating serosa: cT3), or SI (invading adjacent structures: cT4) were recruited after providing informed consent as described elsewhere.[6] Patients with free cancer cells by cytological examination of peritoneal washes and those with type 4 tumor (linitis plastica type) were excluded.

Patients underwent appropriate gastrectomy with systematic lymphadenectomy as allocated by the study protocol. Perigastric lymph nodes (nodal station nos. 1, 3, 4, 5, and 6 according to the Japanese Classification of Gastric Cancer) and nodes at the base of the left gastric artery (no. 7), along the common hepatic artery (no. 8) and at the base of the splenic artery (no. 11) were routinely resected. Lymph nodes along the hepatoduodenal ligament and behind the pancreatic head (nos. 12 and 13) were resected when the primary lesion was located in the lower third of the stomach. Lymph nodes along the left side of the cardia (no. 2), within the splenogastric ligament (no. 4sa) and at the splenic hilum (no. 10), were resected with the spleen when total or proximal gastrectomy was performed. In patients randomized to a D3 lymphadenectomy group, para-aortic lymph nodes from the level of the celiac trunk down to the root of the inferior mesenteric artery (nos. 16a2 and 16b1) were dissected. The mode of reconstruction after resection was not specified.

Information on complications (including major surgical complications) and patient backgrounds (including height and body weight) was extracted from the case report forms for the trial. In this study, anastomotic leakage, pancreatic fistula, and abdominal abscess are defined as surgical complications. Anastomotic leakage was defined as dehiscence confirmed by radiographic examination that used contrast medium. Pancreatic fistula was diagnosed if

there was prolonged purulent discharge that contained pancreatic juice from the drainage tube. In addition, pneumonia and other complications were evaluated as complications.

According to the World Health Organization classification, BMI ≥ 25 is considered as overweight and BMI < 25 as nonoverweight.[7] Factors that might affect the risk of overall and major surgical complications, such as sex, age, tumor location, pathological (p) T category (pT2 and pT3 vs. pT4), extent of lymphadenectomy, type of gastrectomy, splenectomy, and pancreatectomy were evaluated as potential confounding factors. The difference in the distribution of these factors between BMI < 25 and BMI ≥ 25 were examined by χ^2 test. The effect of overweight on the complications was evaluated by odds ratio. In addition, the effect of overweight on operating time, amount of blood loss, need for autologous blood transfusion, reoperation, and hospital death was also evaluated by odds ratio. Operating time, blood loss, and the number of retrieved lymph nodes were divided into tertiles as previously described[8] and used as binary variables by dichotomizing the highest tertiles and the remaining two tertiles because biologically meaningful cutoff points could not be defined. In addition to the univariate analysis, all the analyses were conducted adjusting all the potential confounding factors by logistic regression.

To evaluate the effect of overweight on complications, logistic regression on the complications were conducted with overweight as exposure and operating time and blood loss as intermediate factors in addition to the other potential confounding variables. This analysis reveals whether overweight affects complications directly, or indirectly through these intermediate factors.

To see the difference of the effect of overweight between D2 and D3 dissection, all the analyses were repeated separately for the D2 and D3 subgroups, and these interactions were also evaluated. All statistical analyses were performed SAS software version 8.12 (SAS Institute, Tokyo, Japan). *P* values less than .05 were considered statistically significant, and all tests were two-sided.

RESULTS

Seventy-seven patients were classified as overweight with BMI ≥ 25, and 38 and 39 of these patients underwent D2 or D3 lymphadenectomy, respectively. In 446 patients classified as nonoverweight with BMI < 25, 225 received D2 and 221 received D3 lymphadenectomy. Total gastrectomy was performed in 199 (38.0%) of 523 patients and proximal gastrectomy in 4; the remaining patients underwent distal gastrectomy. Splenectomy was performed in 191 patients (36.5%) and distal pancreatectomy in 22 (4.2%). The background characteristics of patients with different BMIs are listed in Table 1. There were no statistically significant differences in sex, age, tumor location, clinical T stage, lymph node dissection, type of gastrectomy, and incidence of combined resection between the two groups, and the two groups were well balanced.

TABLE 1. *Backgrounds of patients according to body mass index (BMI)*

Factor	BMI < 25 (n = 446)	BMI ≥ 25 (n = 77)	Total number	*P* value
Sex				
M	301	57	358	.26
F	145	20	165	
Age				
< 56	137	23	160	.93
56–65	176	31	207	
> 65	133	23	156	
Location				
A (lower third)	188	29	217	.59
M (middle third)	173	33	206	
C (upper third)	85	15	100	
Clinical tumor stage				
cT2b	161	31	192	.38
cT3	268	41	309	
cT4	17	5	22	
Lymph node dissection				
D2	225	38	263	.86
D3	221	39	260	
Type of gastrectomy				
Distal	272	48	320	.82
Total/proximal	174	29	203	
Splenectomy				
No	283	49	332	.98
Yes	163	28	191	
Pancreatectomy				
No	427	74	501	.88
Yes	19	3	22	

In the entire sample, any complications were identified in 128 patients (24.5%), and major surgical complications occurred in 49 patients (9.4%). Among overweight patients, however, the proportion developing either any or surgical complications was 35.1% and 19.5%, respectively. When assessed by univariate analysis, overweight statistically significantly increased the risk for pancreatic fistula, abdominal abscess, operation time, and blood loss (Table 2). Additionally, the number of retrieved lymph nodes was less in overweight patients. Multivariate analysis identified that overweight was significantly associated

TABLE 2. *Effect of overweight on postoperative complications and other outcome variables*[a]

Factors	BMI < 25	BMI ≥ 25	Univariate analysis: Odds ratio of BMI > 25 (95% CI)	Univariate analysis: *P* value	Multivariate analysis: Odds ratio of BMI > 25 (95% CI)	Multivariate analysis: *P* value
Operation time (min)						
>297	141	36	1.90 (1.16–3.10)	.01	2.24 (1.29–3.87)	.004
≤297	305	41	–		–	
Blood loss (mL)						
>710	131	44	3.21 (1.95–5.26)	<.001	3.74 (2.19–6.39)	<.001
≤710	315	33	–		–	
Blood transfusion						
Yes	98	17	1.01 (.56–1.80)	.98	1.10 (.59–2.03)	.77
No	348	60	–		–	
No. of retrieved lymph nodes						
≤54	137	33	1.69 (1.03–2.77)	.037	1.82 (1.06–3.14)	.031
>54	309	44	–		–	
Reoperation						
Yes	9	3	1.97 (.52–7.44)	.32	1.85 (.47–7.29)	.38
No	437	74	–		–	
Hospital death						
Yes	3	1	1.94 (.20–18.92)	.56	1.96 (.20–19.50)	.56
No	443	76	–		–	
Any complication						
Yes	101	27	1.84 (1.10–3.10)	.021	1.90 (1.11–3.24)	.019
No	345	50	–		–	
Surgical complication						
Yes	34	15	2.93 (1.51–5.69)	.002	3.35 (1.65–6.78)	<.001
No	412	62	–		–	
Anastomotic leak						
Yes	8	3	2.22 (.58–8.56)	.25	2.14 (.54–8.47)	.28
No	438	74	–		–	
Pancreatic fistula						
Yes	20	10	3.18 (1.43–7.09)	.005	4.18 (1.71–10.22)	.002
No	426	67	–		–	
Abdominal abscess						
Yes	19	10	3.35 (1.50–7.52)	.003	3.51 (1.52–8.12)	.003
No	427	67	–		–	
Pneumonia						
Yes	12	4	1.98 (.62–6.31)	.25	1.88 (.58–6.13)	.29
No	434	73	–		–	
Other complication						
Yes	65	11	0.98 (.49–1.95)	.95	0.97 (.48–1.95)	.93
No	381	66	–		–	

BMI, body mass index; 95% CI, 95% confidence interval.

[a] Multivariate covariables: BMI, sex, age, tumor location, clinical tumor stage, lymph node dissection, type of gastrectomy, splenectomy, pancreatectomy.

with pancreatic fistula, abdominal abscess, operation time, and blood loss, and the odds ratios (95% confidence intervals) were 4.18 (1.71–10.22), 3.51 (1.52–8.12), 2.24 (1.29–3.87), and 3.74 (2.19–6.39), respectively. The number of retrieved lymph nodes decreased in overweight patients with an odds ratio of 1.82 (1.06–3.14). When operation time and blood loss were treated as intermediate factors, the odds ratios for the development of pancreatic fistula and abdominal abscess decreased to 3.48 and 2.47, respectively, but were still statistically significant.

We next analyzed the D2 (n = 263) and D3 (n = 260) dissection subgroups (Table 3). In the D2 subgroup, overweight was significantly associated with pancreatic fistula, abdominal abscess, and blood loss with odds ratios (95% confidence intervals) of 4.74 (1.42–15.89), 4.72 (1.49–14.99), and 2.83 (1.33–6.04), respectively. In the D3 subgroup, only blood loss with an odds ratio of 5.05 (2.27–11.26) and operation time with an odds ratio of 2.27 were significantly associated with overweight, although the interaction *P* values between the D2 and D3 subgroups were not statistically significant for any of the factors examined.

DISCUSSION

We clearly showed that overweight patients are at increased risk for the development of organ/space

TABLE 3. *Effect of overweight on postoperative complications and other outcome variables stratified with lymph node dissection (D2 or D3)*[a]

Factor	D2 subgroup (n = 263)		D3 subgroup (n = 260)		
	Multivariate odds ratio of BMI ≥ 25 (95% CI)	*P* value	Multivariate odds ratio of BMI ≥ 25 (95% CI)	*P* value	Interaction *P* value
Operation time					
Operation time >297 min	2.19 (.96–5.02)	.063	2.27 (1.09–4.73)	.028	.95
Blood loss >710 mL	2.83 (1.33–6.04)	.007	5.05 (2.27–11.26)	<.001	.30
Blood transfusion	1.73 (.70–4.26)	.23	0.78 (.34–1.79)	.56	.20
No. of retrieved lymph nodes ≤54	2.73 (1.28–5.85)	.01	1.06 (.43–2.62)	.9	.12
Reoperation	4.21 (.64–27.61)	.13	0.82 (.09–7.39)	.86	.27
Hospital death	6.82 (.40–117.43)	.19	NE	.98	.94
Any complication	2.62 (1.23–5.61)	.013	1.39 (.65–2.98)	.4	.25
Surgical complications	4.20 (1.59–11.10)	.004	2.60 (.91–7.40)	.074	.51
Anastomotic leak	2.77 (.47–16.19)	.26	1.49 (.16–14.09)	.73	.67
Pancreatic fistula	4.74 (1.42–15.89)	.012	3.61 (.96–13.55)	.057	.77
Abdominal abscess	4.72 (1.49–14.99)	.009	2.55 (.73–8.85)	.14	.48
Pneumonia	2.81 (.79–10.04)	.11	NE	.97	.94
Other complications	1.08 (.34–3.37)	.9	0.91 (.37–2.23)	.83	.82

BMI, body mass index; NE, not able to estimate.
[a] Covariables: BMI, sex, age, tumor location, clinical tumor stage, type of gastrectomy, splenectomy, pancreatectomy.

surgical site infection (SSI) (abdominal abscess and pancreatic fistula) complications after gastrectomy with D2 or D3 dissection. Risk factors for the development of SSI in abdominal surgery have been intensively investigated. The presence of a preoperative cutaneous abscess or necrosis, sutures or anastomoses of the bowel, postoperative abdominal drainage, surgical treatment for cancer, and postoperative anticoagulant therapy were identified as risk factors for SSI in noncolorectal abdominal surgery.[9] However, others reported that operation time was the only statistically significant risk factor for SSI after gastrectomy,[10] and in colorectal surgery, diabetes and a 10% weight loss were associated with SSI.[11] Among all of these studies, overweight was not identified as a risk factor for SSI. BMI exhibited a direct relationship with operation time in cholecystectomy, colectomy, and unilateral mastectomy, but it was not associated with surgical complications.[12] Thus, BMI may not directly influence the occurrence of surgical complications or SSI in abdominal surgery, but increased operation time and blood loss secondary to BMI may be responsible for any identified negative outcomes. However, we analyzed operation time and blood loss as intermediate factors instead of outcome variables, and BMI was still associated with the development of pancreatic fistula and abdominal abscess, as seen previously.[8] This fact suggests that BMI has a direct effect on surgical complications besides indirect effects through operation time or blood loss.

Practically, the presence of a large amount of the viscera may disturb drainage of exudates and coagula, and excess fatty tissue may become necrotic more easily as a result of surgical manipulation. In addition, the demarcation between pancreas and fat tissues in overweight individuals is obscure because of greater fat deposition in the pancreas.[13,14] This could also be relevant in cases of gastrectomy requiring peripancreatic nodal dissection and mobilization of the pancreas. These factors may contribute to the increased occurrence of abdominal abscess and pancreatic fistula in overweight surgical patients.

Whites in general have a higher BMI than Japanese individuals, and the incidence of morbid obesity is marked and growing among patients in the United States and Europe. The proportions of patients with BMI ≥ 25 and BMI > 30 in the present study were only 14.7% and 1.0%, respectively, whereas one-third of the U.S. population is obese (BMI > 27).[15] These differences in patients' physique may partly explain observed differences in mortality and morbidity between the UK Medical Research Council (MRC) and Dutch trials and the present study.[16,17] The mortality of patients undergoing D2 dissection in the two Western studies was 13% and 10%, whereas morbidity was 46% and 43%. In contrast, we observed only 1.3% mortality and 35.1% morbidity in overweight patients undergoing D2 or D3 dissection. In addition to possible differences in patients' physique, experience and workload volume of surgeons are important factors that could contribute to different surgical outcomes.

In patients undergoing D2, but not D3, dissection, overweight was associated with surgical complications. Although these differences were not statistically

significant, this may be because of low statistical power to test the interactions. In contrast, only the odds ratios of long operation time and excessive blood loss increased were statistically significant in the D3 dissection group, as reported previously.[6] The increased risk of complications in nonoverweight patients in the D3 subgroup could explain these differences. Indeed, the cumulative incidence of all complications in normal patients was 17.8% in the D2 subgroup and 27.6% in the D3 subgroup. Thus, greater care should be taken in performing gastrectomy not only in all patients undergoing D3 dissection, but also in overweight patients undergoing D2 dissection.

The relationship between overweight and overall prognosis in patients with cancer is an important issue to resolve. The presence of excess fat impairs precise nodal dissection and decreases the yield of lymph nodes. In this study, the number of lymph nodes retrieved from overweight patients was far less compared with nonoverweight patients undergoing a D2, but not D3, dissection. In addition to the quality of lymph node dissection, comorbid conditions associated with overweight, such as cardiovascular diseases, pulmonary dysfunction, diabetes, and hypertension, may negatively affect the prognosis of postoperative patients.[18] The relationship between overweight and overall survival in patients with gastric cancer remains controversial.[1–4] A conclusive result cannot be obtained without a well-controlled prospective study, and the final results of the JCOG9501 trial should answer this important question. However, the present study provides some insight into this issue.

The proportion of overweight patients in this trial was low (14.7%). Therefore, the obtained results are not definitely conclusive, but they clearly suggest that caution is needed when performing gastrectomy for gastric cancer in overweight patients. In conclusion, overweight increased the risk of surgical complications in patients undergoing gastrectomy with lymphadenectomy.

ACKNOWLEDGMENTS

Supported in part by Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare and the Second Term Comprehensive 10-Year Strategy for Cancer Control by the Ministry of Health and Welfare, Japan. The authors thank Dr. Yoshimura for help with the statistical analysis, Ms. Hongo for data management, and Ms. Sugimoto for secretarial assistance. Participating institutions and chief participants: National Cancer Center Hospital (M. Sasako, T. Sano), Niigata Cancer Center Hospital (A. Nashimoto, H. Yabuzaki), National Shikoku Cancer Centre (A. Kurita, Y. Kubo), Osaka Medical Center for Cancer and Cardiovascular Diseases (M. Hiratsuka, I. Miyashiro), Osaka National Hospital (K.Fujitani, M. Hirao), National Cancer Centre Hospital East (T. Kinoshita), Tokyo Metropolitan Komagome Hospital (K. Arai, Y. Iwasaki), Aichi Cancer Centre (T. Kito, Y. Yamamura), Osaka Medical College (K. Okajima, M. Tanigawa), International Medical Centre of Japan (O. Kobori, T. Shimizu), Sakai City Hospital, Kanagawa Cancer Centre (H. Furukawa, H. Imamura), Tokyo Metropolitan Bokuto Hospital (M. Kitamura, S. Inoue), Nagaoka Chuo General Hospital (T. Yoshikawa, T. Shimizu), Niigata City General Hospital (K. Aizawa), Cancer Institute Hospital (K. Ota, S. Oyama), Kyoto Second Red Cross Hospital (H. Tokuda, S. Takahashi), Saitama Cancer Centre, Hiroshima City Hospital (Y. Tanaka, K. Uchida), Kanazawa University (K. Miwa, T. Fujimura), Gifu Municipal Hospital (H. Tanemura, H. Oshita), Kagoshima University (T. Aiko, S. Hokita), Iwate Medical University (M. Terashima, K. Saito), and Okayama University (H. Isozaki).

REFERENCES

1. Kodera Y, Ito S, Yamamura Y, et al. Obesity and outcome of distal gastrectomy with D2 lymphadenectomy for carcinoma. *Hepatogastroenterology* 2004; 51:1225–8.
2. Inagawa S, Adachi S, Oda T, Kawamoto T, Koike N, Fukao K. Effect of fat volume on postoperative complications and survival rate after D2 dissection for gastric cancer. *Gastric Cancer* 2000; 3:141–4.
3. Dhar DK, Kubota H, Tachibana M, et al. Body mass index determines the success of lymph node dissection and predicts the outcome of gastric carcinoma patients. *Oncology* 2000; 59:18–23.
4. Barry JM, Blackshaw GRJC, Edwards P, et al. Western body mass indices need not compromise outcomes after modified D2 gastrecgtomy for carcinoma. *Gastric Cancer* 2003; 6:80–5.
5. Moriwaki Y, Kunisaki C, Kobayashi S, Harada H, Imai S, Kasaoka C. Does body mass index (BMI) influence morbidity and long-term survival in gastric cancer patients after gastrectomy?. *Hepatogastroenterology* 2003; 50:284–8.
6. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: results of morbidity and mortality of a prospective randomized trial (JCOG9501) comparing D2 and extended para-aortic lymphadenectomy. *J Clin Oncol* 2004; 22:2767–73.
7. Seidell JC, Flegal KM. Assessing obesity: classification and epidemiology. *Br Med Bull* 1997; 53:238–52.
8. Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A. Identification of risk factors for the development of complications following extended and superextended lymphadenectomy for gastric cancer. *Br J Surg* 2005; 92:1103–9.

9. Pessaux P, Msika S, Atalla D, Hay J-M, Flamant Y. Risk factors for postoperative infectious complications in noncolorectal abdominal surgery: a multivariate analysis based on a prospective multicenter study of 4718 patients. *Arch Surg* 2003; 138:314–24.
10. Imai E, Ueda M, Kanao K, Miyaki K, Kubota T, Kitajima M. Surgical site infection surveillance after open gastrectomy and risk factors for surgical site infection. *J Infect Chemother* 2005; 11:141–5.
11. Tang R, Chen HH, Wang YL, et al. Risk factors for surgical site infection after elective resection of the colon and rectum: a single-center prospective study of 2,809 consecutive patients. *Ann Surg* 2001; 234:181–9.
12. Hawn MT, Bian J, Leeth RR, et al. Impact of obesity on resource utilization for general surgery procedures. *Ann Surg* 2005; 241:821–8.
13. Yeo C, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. *Ann Surg* 1995; 222:580–8.
14. Yang YM, Tian XD, Zhuang Y, Wang WM, Wan YL, Huang YT. Risk factors of pancreatic leakage after pancreaticoduodenctomy. *World J Gastroenterol* 2005; 11:2456–61.
15. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. *JAMA* 1994; 272:205–11.
16. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resection for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. *The Surgical Cooperative Group. Lancet* 1996; 347:995–9.
17. Bonenkamp JJ, Songun K, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. *Lancet* 1995; 345:745–8.
18. Pi-Sunyer FX. Medical hazards of obesity. *Ann Intern Med* 1993; 119:655–60.

Leading article

Tailoring treatments for curable gastric cancer

T. Sano

Gastric Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan
(e-mail: tksano@ncc.go.jp)

Published online in Wiley InterScience (www.bjs.co.uk). **DOI:** 10.1002/bjs.5785

Although its incidence is decreasing worldwide, gastric cancer is still a major cause of death. There is remarkable geographic variation, with 60 per cent of cases arising in Eastern Asia. In Japan and Korea, public access to endoscopy is assured and almost half of newly diagnosed patients are detected at an early stage. Surgeons in these countries have been able to develop new and exciting minimally invasive therapeutic options. In the West, on the other hand, most patients still present with advanced disease and the treatment options are limited. Furthermore, Western patients are often obese and unfit for surgery, making optimal gastrectomy difficult. Wherever they are in the world, however, surgeons must lead the treatment strategy for potentially curable gastric cancer because without resection there will be no cure.

Depth of tumour invasion (T) and lymph node metastasis are the most important prognostic factors, and they correlate closely with each other[1]. Clinical staging of lymph node status is unreliable, especially for early tumours, while the preoperative diagnosis of T1, and intraoperative distinction between T1/2 and T3/4, can be made quite accurately. So, unless extensive nodal metastasis is clinically evident, the T-stage serves as a key factor in therapeutic planning.

T1 tumours, or early gastric cancers, have a low risk of nodal metastasis and a gastrectomy with limited lymphadenectomy is sufficient for cure. Pylorus- and/or vagus-preserving gastrectomy, and laparoscopic surgery, are recent options in Japan and Korea. Some T1 tumours are even resected at endoscopy, without surgery[2]. The rationale for endoscopic mucosal resection derives from a meticulous analysis of the lymph node status of a large number of patients treated by gastrectomy; when an endoscopically resected tumour satisfies certain criteria, one can be confident that the patient is very unlikely to have nodal metastasis because hundreds of tumours in the same category have had no associated nodal metastasis. Surgeons should be aware of this option for early tumours, since the avoidance of gastrectomy has significant quality of life benefits for patients.

T2 gastric cancer might be regarded as localized disease, but it is associated with more frequent (over 50 per cent) and extensive nodal metastasis than T1, so sufficient lymphadenectomy should be planned. Systematic dissection of the nodes around the coeliac artery and its branches (D2) permits resection of the positive nodes associated with most T2 tumours. Hepatic metastases are rare. T1 and T2 gastric cancers are localized lesions that can be cured by surgery alone, and surgeons should take that responsibility.

Once the tumour penetrates the serosa (T3) or invades adjacent organs (T4), it begins to spread by routes other than the lymphatic system, notably through peritoneal dissemination and in the portal–hepatic blood. Furthermore, lymph node metastasis from T3/4 tumours sometimes overwhelms the regional network, with cancer cells entering the systemic circulation to cause bone and lung metastases. These are effectively beyond the surgeon's reach. In addition to these metastases, the primary lesion becomes larger and more infiltrative and the chance of obtaining an R0 resection diminishes. As a consequence, more than half the patients with T3/T4 tumours develop local or systemic recurrence of disease, which is almost always fatal.

Some surgeons are inclined to regard T3 and T4 gastric cancers as incurable, but the role of surgery should not be underestimated, even at these stages. Some local recurrence may be prevented by careful gastrectomy. Gastric and duodenal stump recurrence at least should be preventable by careful pre- and intraoperative histological examination of the resection margins. Other local recurrence can be attributed to residual lymph node metastasis around the coeliac artery. Complete clearance of the tumour-bearing nodes by D2 lymphadenectomy should diminish this problem and prolong survival. Japanese surgeons have believed this to be so for many years and two recent randomized controlled trials have now provided evidence to support the 'D2 concept' both directly and indirectly. One is the Taipei single-institution study comparing D1 and former D3 (current D2); this was completed without operative mortality and showed a significant survival benefit for D2[3]. The other is the American Intergroup study in which chemoradiation therapy to the gastric bed after limited lymphadenectomy (D0/D1) significantly decreased the local recurrence rate and increased long-term survival[4]. This can be

interpreted as showing that radiotherapy eliminated residual lymph node metastasis, which would have been removed by D2 resection.

The Intergroup study seems to have changed the standard care for gastric cancer in the USA, but its impact has been weak in Japan and Korea, where D2 lymphadenectomy is routinely and safely performed, and where local recurrence is not a major pattern of relapse. D2 lymphadenectomy is, however, technically demanding, with a pronounced learning curve. Patient fitness for surgery is another important factor for a safe operation, and patient obesity hampers the performance of even the most experienced surgeons[5]. When a safe D2 procedure cannot be expected due to any of these factors, adjuvant chemoradiotherapy might prove an adequate substitute. Surgeons now have alternatives for local tumour control and it is they who should assume responsibility for designing the best treatment for each patient.

Many randomized trials of adjuvant chemotherapy have failed to produce solid evidence of effect in patients with resectable cancers who are at high risk of systemic recurrence. However, the MAGIC trial in Europe has recently shown that a significant survival benefit accrues from peri-operative combination chemotherapy[6]. The role of lymphadenectomy is obscure in this trial because it was not standardized and simply left up to the choice of the individual surgeon. One must interpret the results as demonstrating that peri-operative chemotherapy has enough power to offset the influence of surgical diversity. Since the publication of this trial it has become more important than ever for surgeons to consider the treatment options for their patients before they operate.

In conclusion, the result of treatment for locally advanced gastric cancer is the sum of the effect of local tumour control by surgery, with or without radiotherapy and/or systemic chemotherapy. The role of each treatment modality varies according to the stage of disease, individual patient risk, surgical volume, available chemotherapy regimens and quality of radiotherapy. Evidence of the effect of different combinations of treatments should be established for each clinical circumstance and surgeons should play a key role here.

References

1 Sasako M, Sano T, Katai H, Maruyama K. Radical surgery. In: *Gastric Cancer*. Sugimura T, Sasako M, eds. Oxford University Press: Oxford, 1997; 223–248.

2 Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. *J Clin Oncol* 2005; **23**: 4490–4498.

3 Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF *et al.* Nodal dissection for patients with gastric cancer: a randomised controlled trial. *Lancet Oncol* 2006; **7**: 309–315.

4 Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN *et al.* Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001; **345**: 725–730.

5 Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A *et al.* Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. *Br J Surg* 2005; **92**: 1103–1109.

6 Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M *et al.* Perioperative chemotherapy *versus* surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006; **355**: 11–20.

Digestive Surgery

Dig Surg 2007;24:101–107
DOI: 10.1159/000101896

Published online: April 19, 2007

Surgical Treatment of Advanced Gastric Cancer: Japanese Perspective

M. Sasako M. Saka T. Fukagawa H. Katai T. Sano

Gastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan

Key Words
Esophagogastric junction · Gastric cancer, advanced · Surgical treatment

Abstract
The results of clinical trials regarding surgery of curable advanced gastric cancer and esophagogastric junction (EGJ) tumors are reviewed and summarized. Four clinical trials have evaluated D2 dissection for curable gastric cancer in the West. Two large trials in the UK and the Netherlands failed to prove the efficacy of D2 dissection. However, these trials had critical weak points. As they were carried out in a number of hospitals where there was no experience with this surgery, the quality of surgery and postoperative care were very poor making the hospital mortality unacceptably high. After these trials, an Italian group started a phase II study in 8 hospitals with a relatively high volume to confirm the safety of this procedure for Caucasians. They achieved 3% mortality, which was much smaller than that of even D1 in the former trials. These results first highlighted the importance of learning and hospital volume in D2 dissection. Survival results of the Dutch trial showed some difference between D1 and D2, but the difference was not statistically significant. This was attributed to the high hospital mortality and poor quality of surgery, especially low compliance of D2 and the high rate of extension of D1, making this comparison similar to that between D1.3 and D1.7. The results of the phase III study by the Italian group are awaited. Recently a Taiwanese trial proved the benefit of D2 dissection over D1 in a phase III trial. This was a single institutional trial with a sample size of 221 patients. The 5-year survival rate of D2 and D1 was 59.5 and 53.6%, respectively ($p = 0.04$). The Dutch trials for EGJ tumors showed a large difference in overall survival between the transthoracic and transhiatal approach for Siewert type 1 and 2 tumors, but this was not statistically significant, most likely due to the small sample size. In the subgroup analysis, they demonstrated that there was no survival difference in Siewert type 2 but a large difference in Siewert type 1. A Japanese study showed that there is no benefit to the thoraco-abdominal approach over the transhiatal approach for EGJ tumors whose invasion in the esophagus is 3 cm or less. These two trials clearly demonstrated that mediastinal dissection through a right thoracotomy is recommendable for Siewert type 1, while the transhiatal approach should be considered as standard for Siewert type 2.

Background

In the guidelines of the Japan Gastric Cancer Association, standard surgery for curable advanced gastric cancer is defined as a more than 2/3 gastrectomy with D2 dissection [1]. With the results of several important

KARGER
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

0253–4886/07/0242–0101$23.50/0

Accessible online at:
www.karger.com/dsu

Dr. M. Sasako
National Cancer Center
5-1-1, Tsukiji
Chuo-ku, Tokyo 104 0045 (Japan)
Tel. +81 3 3542 2511, Fax +81 3 3547 6611, E-Mail msasako@gan2.ncc.go.jp

Table 1. Morbidity and mortality after D2 dissection and hospital volume

Trial	Type	n	Number of patients per hospital per year	Mortality %	Morbidity %	Reference
Hong Kong	RCT	30	7.5	3	57	Robertson et al. [7]
MRC	RCT	200	1.5	13	46	Cuschieri et al. [8]
Dutch	RCT	331	1.0	10	43	Bonenkamp et al. [2]
Taiwanese	RCT	211	18.5	0	17	Wu et al. [16]
IGCSG	Phase II	191	8.0	3	21	Degiuli et al. [4]
IGCSG	RCT	82	4.3	0	16	Degiuli et al. [6]
Italian study	Retro	451	21.5	2	17	Roviello et al. [9]

RCT = Randomized controlled trial; MRC = Medical Research Council; IGCSG = Italian Gastric Cancer Study Group.

clinical trials, not only in surgery but also multidisciplinary treatment, this policy of the Japanese guidelines might be challenged. In this article, the Japanese perspective of curative surgery for advanced gastric cancer is explained.

Results of European Trials

There have been four European clinical trials on D2 dissection for curable gastric cancer [2–5]. Three of them were phase III trials and the remainder was the only phase II trial in the world. The phase III trials were carried out by the Medical Research Council (MRC) [3], the Dutch Gastric Cancer Group (DGCG) [2] and the Italian Gastric Cancer Study Group (IGCSG) [5]. The first two trials have already shown negative results, while the long-term results of the last one are awaited. After the first two large phase III trials showed quite high hospital mortality after D2 dissection on Caucasians, the IGCSG started with a phase II study to confirm the safety of the D2 dissection in their population [4].

Morbidity and Mortality of D2 Dissection in These Trials

The Dutch and the MRC studies showed extremely high hospital mortality after D2 dissection, 10 and 13%, respectively. Such a high mortality is no longer accepted for any cancer surgery today. These results were heavily criticized and attributed to a very low hospital volume [6]. Table 1 shows the clear negative correlation between hospital volume and hospital mortality after D2 dissection in the literature. This high mortality was also attributed to splenectomy and pancreatectomy. Especially in the MRC trial, many surgeons thought that D2 distal gastrectomy included splenectomy, and splenectomy was carried out in many distal gastrectomy cases [10]. This was based on the misunderstanding of the definition of D2 gastrectomy by the Japanese Research Society for Gastric Cancer [11]. In Japan, splenectomy was included in D2 dissection only when a total gastrectomy was carried out. Together with thorough lymph node dissection of the lesser curvature, splenectomy causes serious ischemia of the remnant stomach, necrosis of the remnant stomach or anastomotic leakage. This was also the case in the DGCG trial [12]. In the multivariate analysis of hospital mortality, splenectomy was one of the factors most responsible for mortality. The lack of experience in treating major surgical complications after D2 dissection, namely, anastomotic leakage, pancreatic fistula (juice leak) or intra-abdominal abscess, led to a much higher mortality than a Japanese specialist center where a few hundred patients were treated yearly (table 2) [6]. With less than a few cases yearly, surgeons can never learn how to treat these major complications to avoid treatment-related death. This high mortality after D2 dissection in the Dutch trial might also be attributed to the greater fragility of the Dutch compared with the Japanese. However, the results of another Dutch trial comparing a transthoracic esophagogastrectomy via right thoracotomy with a transhiatal approach for esophagogastric junction (EGJ) tumors showed a much lower mortality in the both treatment arms, 4% for the former and 2% for the latter [13]. This trial was carried out exclusively in two major cancer hospitals which have a reasonably high hospital volume. This suggests that high mortality in the D1/D2 trial was not attributed to the fragility of the Dutch patients but to the very low hospital volume.

Table 2. Mortality after postoperative major surgical complications

Complication	Dutch trial (n = 711)			NCCH trial (1982–1987; n = 1,197)			p
	deceased patients	affected patients	%	deceased patients	affected patients	%	
Leakage	19	46	41.3	12	84	14.3	0.0005
Distal	9	22	40.1	2	23	8.7	0.012
Total	10	24	41.7	10	60	16.7	0.0047
Abscess or pancreatic fistula	19	91	20.9	2	75	2.7	0.0004

NCCH = National Cancer Center Hospital.

After these two trials with dismal short-term results, the IGCSG started a phase II trial to confirm the safety. Actually a 3% mortality was found in 8 hospitals with a total of 191 patients [4]. They avoided the routine use of distal pancreatectomy in cases of total gastrectomy; instead they adopted pancreas-preserving total gastrectomy, the so-called Maruyama technique [5]. Thus they avoided splenectomy in distal gastrectomy and distal pancreatectomy in total gastrectomy. The morbidity and mortality shown by the phase II study was confirmed by the results of the interim analysis of the IGCSG phase III trial. Hospital mortality was 1.3% after D1 but 0% after D2 gastrectomy in this study [6].

Survival Results after D2 Dissection

In the MRC trial, the survival curve of D2 was never better than that of D1 until the end of the trial. In the Dutch trial, the survival curve of D2 caught up with that of D1 after 4 years and remained superior, but the difference between D1 and D2 survival never reached statistical significance. Practically, in the MRC trial, there was no quality control of surgery and the quality seemed poor due to the mortality. In the Dutch trial, there were several efforts to control the quality of performance including direct tuition of the D2 dissection in the operation theater and quality evaluation by the number of dissected nodes. According to their results, there were many cases in the D1 group where more extended dissection than D1 was actually carried out and many patients in the D2 group underwent less than D2 dissection [14]. Eventually they compared D1.3 versus D1.7, for example, minimizing the difference between the arms. Low-quality surgery together with a much higher mortality immediately after surgery could explain why D2 dissection was not found to be beneficial. In fact, the Italian group showed much better survival results in their phase II trial than those of the Dutch trial [15]. The 5-year survival rates for stages IA, IB, II, IIIA and IIIB were 93, 88, 60, 40 and 20%, respectively, while those in the Dutch trial were 81, 61, 42, 28 and 13%, respectively. Survival results of the phase III study by the IGCSG are awaited.

Results of Taiwanese Trial

Recently a Taiwanese hospital published the results of a phase III study comparing D1 versus D2/3 surgery for curable gastric cancer in a single institution [16]. Their D3 includes lymph node stations in the hepatoduodenal ligament, on the superior mesenteric vein, behind the common hepatic artery and on the posterior pancreatic surface in addition to D2 dissection, according to the 1st English Edition of the Japanese Classification of Gastric Carcinoma [17]. They showed statistically significant improvement in survival by D2/3 surgery over D1. The 5-year overall survival of D2/3 and D1 was 59.5 and 53.6%, respectively ($p = 0.04$; fig. 1). This study included only three surgeons at a single institution, therefore the quality of surgery in this study seemed to be more identical than in multicenter trials. This is the first randomized controlled study which showed significantly better overall survival of D2/3 surgery than D1 in the world. There are several remarkable differences between this study and the Dutch study. Due to the much higher hospital volume and good quality control at a single institution, the hospital mortality after D2/3 was 0% in this study, while it was as high as 10% in the Dutch trial. More patients in the Taiwanese study had antral tumors and underwent distal subtotal gastrectomy than the Dutch trial. The proportion of those who underwent distal subtotal gastrectomy in this study and the Dutch study was 76 and 66%, respectively. Due to the rather small sample size and



Fig. 1. Overall survival curves of the entire patient population by treatment groups in the Dutch trial.

modest survival benefit, this study cannot be considered as solid evidence for the superiority of D2 over D1 dissection.

Results of Adjuvant Chemoradiotherapy

A phase III study comparing surgery alone with postoperative adjuvant chemoradiotherapy (CRT), the INT0116/SWOG9008, showed a large survival benefit of CRT for curable gastric cancer; the median survival time of surgery alone was 27 months, compared with 36 months for CRT [18]. The hazard ratio for death was 1.35 (95% CI 1.09–1.66; p = 0.005). In this trial, the tested arm included curative surgery and radiation therapy of 45 Gy with combination chemotherapy using fluorouracil and leucovorin (5 courses of 5-day continuous infusion, including 2 courses of concomitant administration). However, detailed analysis of the type of surgery revealed that 54 and 36% of the patients underwent D0 and D1 surgery, respectively, while only 10% underwent D2 dissection. Although there was no statistically significant interaction between the subgroups divided by the degree of lymph node dissection and the effect of treatment, a benefit from treatment was observed only in the D0 or D1 group in the subset analysis [19]. In the retrospective detailed analysis, the researchers of this study found that surgical undertreatment clearly undermined the survival of patients [20]. Thus this study for the first time proved the efficacy of local control by radiation for gastric cancer and proved that limited surgery alone cannot be sufficient treatment for this cancer.

The patient population enrolled in the test arm of this study was by chance quite similar to the population enrolled in a Japanese clinical trial comparing surgery alone with surgery followed by adjuvant CTX (JCOG9206-2) [21]. Table 3 shows the tumor and patient characteristics of the 2 groups. Most of the prognostic factors, i.e., histological type, tumor location, age, tumor size, and, most important, tumor depth, were reasonably comparable between the groups. Although these 2 groups were the patients of two different trials with two different treatment methods, they are identical and therefore the treatment results are more or less comparable. The 5-year overall survival was 42 and 61% in the INT0116 and JCOG9206-2, respectively. This suggests strongly that D2 surgery alone might produce better survival than limited surgery followed by CRT and that the effect of adjuvant CTX might not be expected after D2 as suggested by the subgroup analysis.

Surgical Treatment for Esophagogastric Junction Tumors

Hulscher et al. [13] reported the results of a phase III trial for Siewert type 1 and 2 tumors, comparing two surgical approaches, a transthoracic esophagogastrectomy



Fig. 2. Overall survival curves in patients with Siewert type 1 (**a**) and Siewert type 2 (**b**) tumors, by treatment groups. THO = Transthoracic esophagectomy; TTO = transhiatal esophagectomy.

via right thoracotomy with transhiatal one. The overall survival in the entire study population did not show statistically significant differences between the 2 groups. However, the actual difference in the survival curves was impressive and the overall 5-year survival rate was 29% for the transhiatal approach and 39% for the transthoracic one ($p = 0.38$; fig. 1). In the subgroup analysis according to the Siewert classification, the difference in overall 5-year survival was as large as 17% (95% CI –3 to 37%) for Siewert type 1 ($n = 90$), while it was only 1% for Siewert type 2 ($n = 115$; fig. 2) [22]. Due to the small sample size, this study was not able to show any statistically significant difference, but the results strongly suggest that thorough mediastinal dissection via right thoracotomy is needed for Siewert type 1 but not for type 2. With higher morbidity after transthoracic dissection, the transhiatal approach might be better treatment for Siewert type 2.

Sasako et al. [23] reported the results of a phase III trial for Siewert type 2 and 3 tumors, comparing a left thoraco-abdominal approach versus a transhiatal one. All these tumors were diagnosed to have esophageal in-



Fig. 3. Overall survival (**a**) and disease-free survival (**b**) of the entire patient population and overall survival in patients with Siewert type 2 (**c**) and type 3 (**d**) tumors by treatment groups. TH = Transhiatal; LTA = left thoraco-abdominal. Reprinted with permission from *The Lancet Oncology* [23].

Table 3. Comparison between the INT0116 study and JCOG9206-2 study

	IT0116/SWOG9008	JCOG9206-2
Surgery (D0/1/2), %	54/36/10	4/67/33
Adjuvant	Rad (45 Gy)+CX (5FU+LV)	CDDP+5FU+UFT (50%), none (50%)
Number of patients	281 (tested arm)	268 (control = 133, tested = 135)
Tumor location	A (53%), Corp (24%), cardia (21%), multifocal (2%)	L (31%), M (32%), U (28%), wide (9%)
pT (T1/T2/T3/T4)	14/74/175/18	5/87/165/11
Proportion of T3/4, %	69	66
Node positive, %	85	72
TRD	3 (1.1%)	4 (1.5%)
Overall survival (5 years), %	42	control 61, tested 62

Rad = Radiation; CX = chemotherapy; LV = leucovorin; 5FU = 5-fluorouracil; CDDP = cis-diamminedichloroplatinum; UFT = uracil-ftegafur; A = antrum; Corp = gastric body; L = distal one third; M = middle one third; U = upper one third; wide = wide spread; TRD = treatment-related death.

vasion of 3 cm or less. They clearly demonstrated that there was no survival benefit from the left thoraco-abdominal approach which was accompanied by a much higher morbidity and more remarkable deterioration of pulmonary function than the transhiatal approach. The subgroup analysis showed no survival benefit for both Siewert type 2 and 3. Especially for Siewert type 3, the transhiatal approach showed much better survival than the left thoracotomy approach (fig. 3).

From these two trials, the transhiatal approach is regarded as the standard treatment for Siewert type 2 and 3 tumors, while the transthoracic approach via right thoracotomy is recommended for Siewert type 1 tumors.

References

1 Nakajima T: Gastric cancer treatment guideline in Japan. Gastric Cancer 2002;5:1–5.
2 Bonenkamp JJ, Hermans J, Sasako M, van De Velde CJ, et al; Dutch Gastric Cancer Group: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908–914.
3 Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P: Patient survival after D1 and D2 resection for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999;79:1522–1530.
4 Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F: Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol 1998;16:1490–1493.
5 Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okabayashi K: Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995;19:532–536.
6 Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, Scaglione D, Andreone D, Ponti A, Calvo F: Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004;30:303–308.
7 Robertson CS, Chung SC, Woods SD, et al: a prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994;220: 176–182.
8 Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P; Surgical Cooperative Group: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised surgical trial. Lancet 1996; 347:995–999.
9 Roviello F, Marrelli D, Morgagni P, de Manzoni G, Di Leo A, Vindigni C, Saragoni L, Tomezzoli A, Kurihara H, Italian Research Group for Gastric Cancer: Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. Ann Surg Oncol 2002;9:894–900.
10 Sasako M: Principles of surgical treatment for curable gastric cancer. J Clin Oncol 2003; 21(suppl):274s–275s.
11 Japanese Research Society for the Gastric Cancer: The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 1981;11:418–425.
12 Sasako M: Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg 1997;84:1567–1571.
13 Hulscher JBF, van Sandick JW, de Boer AGEM, Wijnhoven BPL, Tijssen JGP, Fockens P, Stalmeier PFM, ten Kate FJW, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJB: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662–1669.
14 Bunt TMG, Bonenkamp JJ, Hermans J, van de Velde CJH, Arends JW, Fleuren G, Bruijn JA: Factors influencing noncompliance and contamination in a randomized trial of 'Western' (R1) versus 'Japanese' (R2) type surgery in gastric cancer. Cancer 1994;73: 1544–1551.
15 Degiuli M, Sasako M, Ponti A, Calvo F: Survival results of a multicenter phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727–1732.
16 Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AFY, Lui WY, Peng JW: Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309–315.
17 Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, ed 1. Tokyo, Kanahara, 1995, p 15.
18 Macdonald JS, Smalley SR, Benedetti J, Este SANC, Stemmermann NG, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.
19 Macdonald JS: Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008). Virtual Meeting of ASCO GI Symposium.
20 Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002;9: 278–286.
21 Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, Kinoshita T, Kobayashi O, Arai K; Gastric Cancer Surgical Study Group of the Japan Clinical Oncology Group: No survival benefit with adjuvant chemotherapy for serosa-positive gastric cancer (JCOG9206-2). Proc 2005 Gastrointestinal Cancer Symp, p 84.
22 Hulscher JBF, van Lanschot JJ: Individualised surgical treatment of patients with an adenocarcinoma of the distal oesophagus or gastro-oesophageal junction. Dig Surg 2005; 22:130–134.
23 Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, Nashimoto A, Hiratsuka M: Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006;7:644–651.

EDITORIAL

We Have Entered a New Era of Adjuvant/Neoadjuvant Therapy For Gastric Cancer

Takeshi Sano, MD
Head, Gastric Surgery Division
National Cancer Center Hospital, Tokyo

The role of local treatment in multimodality therapy varies among cancers. In head and neck cancers, for example, not only the primary tumor but even recurrent disease can be treated for cure by surgery and/or radiotherapy, while breast cancer may be a systemic disease from its early stage, rendering surgery a mere staging procedure to provide information for systemic therapy. Gastric cancer would fall in between; ie, it remains localized for a fairly long time and therefore early detection and tumor resection can bring cure, but the surgical results in later-stage disease are dismal. In gastric cancer, no cure can be expected without surgery, but surgery alone cannot bring cure in many patients. The role of adjuvant therapy is particularly important in such a condition.

Although meta-analyses of numerous trials have suggested benefits of adjuvant chemotherapy for gastric cancer, there had been no pivotal study until recently, and all phase III trials needed a control arm of surgery alone. Now we are in a state of rapid transition. In the three different regions of the world, three different modalities of adjuvant therapy were proven to be effective by large-scale randomized trials. These include postoperative chemoradiation therapy in the Unites States,[1] perioperative three-drug combination chemotherapy in Europe,[2] and postoperative single-drug chemotherapy in Japan.[3]

Since the publication of the INT-0116 study,[1] chemoradiation has become a standard option in the United States, and today, no US clinical trial for resectable gastric cancer is planned without. Preoperative application of this modality is also being vigorously tested.

In Europe, the MAGIC trial showed significant survival benefit of perioperative combination chemotherapy.[2] The completion of the study, however, was not easy and it underwent some major protocol amendments, such as expansion of the eligibility criteria to include patients with esophageal adenocarcinoma. Another European randomized clinical trial of neoadjuvant chemotherapy was halted early due to very slow accrual and some institutions in the study joined the MAGIC trial. Even with these expansive amendments, it took 8 years to recruit 503 patients.

These two landmark studies, INT-0116 and MAGIC, are discussed in detail by Jiang and his colleagues in an article of this issue of *Gastrointestinal Cancer Research*.[4] The authors offer a comprehensive review of adjuvant and neoadjuvant trials and discuss future perspectives, including the role of molecular targeting agents. As this article was in press, the results of the third pivotal trial, Japanese ACTS-GC, were presented at the American Society of Clinical Oncology's 2007 Gastrointestinal Cancers Symposium.[3]

In this trial, 1,059 patients with stage II or III gastric cancer who had undergone curative D2 gastrectomy were randomized to either observation or 1-year administration of oral S-1. Surprisingly, the study was terminated at the first interim analysis in 2006 due to a highly significant difference of survival in favor of chemotherapy. Now that we suddenly have three different effective modalities, we naturally wonder which is best for resectable gastric cancer.

INTERPRETING STUDY RESULTS

In their review article, Jiang et al suggested superiority of postoperative chemoradiotherapy to perioperative chemotherapy by pointing out the better 2-year survival rate of the experimental arm in INT-0116 than that in MAGIC (58% vs. 48%), despite the higher incidence of nodal metastasis in the former trial (85% vs. 72%). However, this simple comparison may be misleading because these two trials targeted distinct populations.

In INT-0116, only patients who had undergone curative surgery were enrolled whereas in MAGIC, 28% of the control arm turned out to be noncurative at surgery. In addition, the proportion of node-positive cases in the MAGIC trial (72%) is likely an underestimate, because the nodal status was available in only 156 of 185 gastric cancer patients, leaving unresectable cases, which were highly likely to have nodal metastasis, uncounted. Indeed, not only the experimental group but also the surgery alone group of INT-0116 showed higher 2-year survival rates than that of MAGIC (52% vs. 40%). As Jiang et al concluded, a prospective comparative study is needed to give the answer. It is desirable that, in future neoadjuvant trials, staging laparoscopy should be included in preregistration work-ups to exclude cases of peritoneal disease.

It may not be appropriate to compare the Japanese ACTS-GC trial in the same vein as the other studies. The 3-year overall survival rates of the control and experimental groups in this study were 70% and 81%, respectively. These figures were remarkably higher than the corresponding figures of 41% and 50% in INT-0116 and still lower ones in MAGIC, despite its highest proportion of nodal metastasis (89%). This could be attributable to patient selection and staging. In the Japanese trial, the eligibility criteria included D2 or more extended lymphadenectomy (thus, with complete data of nodal staging), and negative peritoneal cytology (thus, with low possibility of peritoneal recurrence).

In both Western trials, the survival rates of the control group were lower than 30% at 5 years, indicating that these studies targeted poor-prognosis populations. In order to challenge such a condition, it would be permissible to add toxic combination therapy to surgery in all patients, even if it was associated with some treatment-related mortality. However, in a situation where more than half of the patients are expected to survive with surgery alone, physicians hesitate to use highly toxic adjuvant or neoadjuvant therapy. In this